(Q78733789)

English

Rate of biodistribution of STEALTH liposomes to tumor and skin: influence of liposome diameter and implications for toxicity and therapeutic activity

scientific article published on 01 January 2003

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12507764%20AND%20SRC:MED&resulttype=core&format=json

16 December 2019

Rate of biodistribution of STEALTH liposomes to tumor and skin: influence of liposome diameter and implications for toxicity and therapeutic activity (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12507764%20AND%20SRC:MED&resulttype=core&format=json

16 December 2019

author name string

Gregory J R Charrois

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12507764%20AND%20SRC:MED&resulttype=core&format=json

16 December 2019

Theresa M Allen

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12507764%20AND%20SRC:MED&resulttype=core&format=json

16 December 2019

language of work or name

0 references

publication date

1 January 2003

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12507764%20AND%20SRC:MED&resulttype=core&format=json

16 December 2019

Biochimica et Biophysica Acta

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12507764%20AND%20SRC:MED&resulttype=core&format=json

16 December 2019

1609

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12507764%20AND%20SRC:MED&resulttype=core&format=json

16 December 2019

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12507764%20AND%20SRC:MED&resulttype=core&format=json

16 December 2019

102-108

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12507764%20AND%20SRC:MED&resulttype=core&format=json

16 December 2019

Efficacy of pegylated-liposomal doxorubicin in the treatment of AIDS-related Kaposi's sarcoma after failure of standard chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2736%2802%2900661-2

7 January 2021

Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation.

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2736%2802%2900661-2

7 January 2021

Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2736%2802%2900661-2

7 January 2021

The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi's sarcoma patients treated with pegylated liposomal doxorubicin

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2736%2802%2900661-2

7 January 2021

Phase II study of pegylated liposomal doxorubicin: inactive in recurrent small-cell lung cancer. A Hellenic Cooperative Oncology Group Study

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2736%2802%2900661-2

7 January 2021

Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2736%2802%2900661-2

7 January 2021

Phase I study of stealth liposomal doxorubicin in combination with gemcitabine in the treatment of patients with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2736%2802%2900661-2

7 January 2021

Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2736%2802%2900661-2

7 January 2021

Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2736%2802%2900661-2

7 January 2021

Skin toxic effects of polyethylene glycol-coated liposomal doxorubicin

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2736%2802%2900661-2

7 January 2021

Chemotherapy-associated palmar-plantar erythrodysesthesia syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2736%2802%2900661-2

7 January 2021

Hand-foot syndrome associated with liposome-encapsulated doxorubicin therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2736%2802%2900661-2

7 January 2021

The costs and efficacy of liposomal doxorubicin in platinum-refractory ovarian cancer in heavily pretreated patients

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2736%2802%2900661-2

7 January 2021

Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with continuous 5-fluorouracil infusion

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2736%2802%2900661-2

7 January 2021

Topical DMSO treatment for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2736%2802%2900661-2

7 January 2021

Clinical studies of liposome-encapsulated doxorubicin

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2736%2802%2900661-2

7 January 2021

Relationship of dose intensity to the induction of palmar-plantar erythrodysesthia by pegylated liposomal doxorubicin in dogs

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2736%2802%2900661-2

7 January 2021

Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2736%2802%2900661-2

7 January 2021

Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2736%2802%2900661-2

7 January 2021

Liposome disposition in vivo. III. Dose and vesicle-size effects

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2736%2802%2900661-2

7 January 2021

Liposomes with prolonged circulation times: factors affecting uptake by reticuloendothelial and other tissues

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2736%2802%2900661-2

7 January 2021

125I labelled inulin: a convenient marker for deposition of liposomal contents in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2736%2802%2900661-2

7 January 2021

Anti-MUC-1 immunoliposomal doxorubicin in the treatment of murine models of metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2736%2802%2900661-2

7 January 2021

Subcutaneous administration of liposomes: a comparison with the intravenous and intraperitoneal routes of injection

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2736%2802%2900661-2

7 January 2021

Size-dependent extravasation and interstitial localization of polyethyleneglycol liposomes in solid tumor-bearing mice

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2736%2802%2900661-2

7 January 2021

Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2736%2802%2900661-2

7 January 2021

The role of surface charge and hydrophilic groups on liposome clearance in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2736%2802%2900661-2

7 January 2021

Openings between defective endothelial cells explain tumor vessel leakiness

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2736%2802%2900661-2

7 January 2021

Effect of vesicle size and lipid composition on the in vivo tumor selectivity and toxicity of the non-cross-resistant anthracycline annamycin incorporated in liposomes

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2736%2802%2900661-2

7 January 2021

Controlled destabilization of a liposomal drug delivery system enhances mitoxantrone antitumor activity

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2736%2802%2900661-2

7 January 2021

Identifiers

10.1016/S0005-2736(02)00661-2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12507764%20AND%20SRC:MED&resulttype=core&format=json

16 December 2019

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12507764%20AND%20SRC:MED&resulttype=core&format=json

16 December 2019

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q78733789&oldid=1614796408"